<DOC>
	<DOCNO>NCT00139633</DOCNO>
	<brief_summary>This prospective study design assess outcome ( survival failure pattern ) therapy localize esophageal cancer conventional dose radiation ( RT ; 50.4 Gy ) concurrent continuous infusion 5-fluorouracil ( 5-FU ) weekly carboplatin/paclitaxel . Patients less complete response ( CR ) partial response ( PR ) receive dose escalation radiation 59.4 Gy chemotherapy .</brief_summary>
	<brief_title>Selective Dose Escalation Esophageal Cancer</brief_title>
	<detailed_description>prospectively enrolled patient T1–4 , N0–1 , M0–1a esophageal carcinoma receive paclitaxel 45 mg/m2 IV 1 hour carboplatin AUC 2 IV 30 minute day 1 , 8 , 15 , 22 , 29 36 . 5-FU 225mg/m2 deliver continuous infusion day 1–38 . RT give 1.8Gy 5 days/wk 5.5 wks ( 50.4Gy 28 fx ) . After 6–8 week , patient underwent repeat stag compute tomography ( CT ) scan , endoscopic ultrasound ( EUS ) , biopsy . Patients positive biopsy , less PR CT EUS , receive boost 9 Gy concurrent chemotherapy . Patients follow every 4 month CT/EUS first year , every 6 month thereafter .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>T1–4 , N0–1 , M0–1a esophageal carcinoma distant metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>esophageal cancer , chemotherapy , radiation</keyword>
</DOC>